Skip to main content
SpringerLink
Log in

Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 995))

Abstract

Cancer therapies are toxic. Newer oncological treatments such as immunotherapy produce unconventional adverse events that are collectively referred to as immune-related adverse events (irAEs). These irAEs are clinician-rated and typically reported via tabulation of adverse events from the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). However, the symptomatic effects of treatment and the severity of disease are best reported by the patient themselves. Although many pivotal trials for immunotherapeutic agents include health-related quality-of-life measures, symptom-focused assessments are more proximal to the effects of treatment and disease burden. This chapter discusses how best to measure symptoms, describes the desirable properties of a psychometrically valid symptom assessment tool, reviews available symptom assessment tools, provides methods to assist in the interpretation of PRO data, elucidates the feasibility and benefit of incorporating PRO in several cancer cohorts, describes the current use of PROs in immunotherapy, and identifies areas where further research are needed to enhance the use of PROs in cancer patients undergoing immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Patient-Reported Outcomes Measurement Information System. Welcome to PROMIS. Available from: http://www.nihpromis.org. Accessed 26 June 2018.

  2. US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf. Accessed 26 June 2018.

  3. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9). pii: dju244.

    Google Scholar 

  4. de Haes JC. Quality of life: conceptual and theoretical considerations. In: Watson M, Greer S, Thomas C, editors. Psychosocial oncology. Oxford: Pergamon Press; 1988. p. 61–70.

    Google Scholar 

  5. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  6. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.

    Article  CAS  PubMed  Google Scholar 

  7. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  8. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;(37):16–21.

    Google Scholar 

  9. Crocker LM, Algina J. Introduction to classical and modern test theory. Pacific Grove: Wadsworth Publishing; 2006.

    Google Scholar 

  10. Litwin MS. How to measure survey reliability and validity, vol. 7: The survey kit. Thousand Oaks: Sage; 1995.

    Book  Google Scholar 

  11. Nunnally JC, Bernstein IH. Psychometric theory, vol. 3. New York: McGraw-Hill; 1994. McGraw-Hill Series in Psychology

    Google Scholar 

  12. American Educational Research Association, American Psychological Association, National Council on Measurement in Education, Joint Committee on Standards for Educational and Psychological Testing. Standards for educational and psychological testing. 2nd ed. Washington, DC: American Educational Research Association; 1999.

    Google Scholar 

  13. Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS. Patient-reported outcomes: instrument development and selection issues. Value Health. 2007;10(s2):S86–93.

    Article  PubMed  Google Scholar 

  14. Willis GB, Reeve BB, Barofsky I, Invited Paper C. The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessment. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer: measures, methods and applications. Cambridge: Cambridge University Press; 2004. p. 610–22.

    Chapter  Google Scholar 

  15. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.

    Article  PubMed  Google Scholar 

  16. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.

    CAS  PubMed  Google Scholar 

  17. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Issues in pain measurement, vol. 12: Advances in pain research and therapy. New York: Raven Press; 1989. p. 391–403.

    Google Scholar 

  18. Dworkin RH, Turk DC, Revicki DA, et al. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain. 2009;144(1–2):35–42.

    Article  PubMed  Google Scholar 

  19. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186–96.

    Article  CAS  PubMed  Google Scholar 

  20. Lai JS, Crane PK, Cella D. Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res. 2006;15(7):1179–90.

    Article  PubMed  Google Scholar 

  21. Okuyama T, Akechi T, Kugaya A, et al. Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage. 2000;19(1):5–14.

    Article  CAS  PubMed  Google Scholar 

  22. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998;7(4):301–10.

    Article  CAS  PubMed  Google Scholar 

  23. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13–9.

    CAS  PubMed  Google Scholar 

  24. Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res. 1991;36(3):291–8.

    Article  CAS  PubMed  Google Scholar 

  25. Smets EM, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25.

    Article  CAS  PubMed  Google Scholar 

  26. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum. 1998;25(4):677–84.

    CAS  PubMed  Google Scholar 

  27. Schwartz AL. The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum. 1998;25(4):711–7.

    CAS  PubMed  Google Scholar 

  28. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–9.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, et al. Feasibility of patient reporting of symptomatic adverse events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. Int J Radiat Oncol Biol Phys. 2017;98(2):409–18.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.

    Article  CAS  PubMed  Google Scholar 

  31. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62(6):1034–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1(5):373-378.

    Article  Google Scholar 

  33. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326–36.

    Article  CAS  PubMed  Google Scholar 

  34. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.

    CAS  PubMed  Google Scholar 

  35. Hoekstra J, Bindels PJ, van Duijn NP, Schadé E. The symptom monitor. A diary for monitoring physical symptoms for cancer patients in palliative care: feasibility, reliability and compliance. J Pain Symptom Manage. 2004;27(1):24–35.

    Article  PubMed  Google Scholar 

  36. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9.

    Article  PubMed  Google Scholar 

  37. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371–83.

    Article  PubMed  Google Scholar 

  38. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.

    PubMed  Google Scholar 

  39. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat. 2004;14(1):73–96.

    Article  CAS  PubMed  Google Scholar 

  40. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Earlbaum; 1988.

    Google Scholar 

  41. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52(9):861–73.

    Article  CAS  PubMed  Google Scholar 

  42. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987;40(2):171–8.

    Article  CAS  PubMed  Google Scholar 

  43. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277–84.

    Article  CAS  PubMed  Google Scholar 

  44. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manag. 2005;29(4):401–10.

    Article  Google Scholar 

  45. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20(5):309–18.

    Article  PubMed  Google Scholar 

  46. Cleeland CS, Portenoy RK, Rue M, et al. Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Ann Oncol. 2005;16(6):972–80.

    Article  CAS  PubMed  Google Scholar 

  47. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004;291(9):1092–9.

    Article  CAS  PubMed  Google Scholar 

  48. Wang XS, Shi Q, Yue J, Chen TY, Xu T, Komaki R, et al. Predictive value of patient-reported outcomes on radiation pneumonitis related normal lung uptake of FDG on PET in patients with non-small cell lung cancer treated with concurrent chemoradiation [abstract 3015]. International Society for Quality of Life Research 23rd annual conference; Copenhagen, Denmark; Oct 19-22, 2016. Qual Life Res. 2016;25(Suppl 1):157–8.

    Google Scholar 

  49. Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010;116(1):137–45.

    PubMed  Google Scholar 

  50. Barney BJ, Wang XS, Lu C, Liao Z, Johnson VE, Cleeland CS, et al. Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Qual Life Res. 2013;22(8):2143–50. PMCID: PMC3724766.

    Article  PubMed  Google Scholar 

  51. Williams LA, Giralt SA, Wang XS, Mobley GM, Mendoza TR, Cohen MZ, et al., editors. Measuring the symptom burden of allogeneic hematopoietic stem cell transplantation in patients with and without acute graft-versus-host disease [abstract 49]. Biol Blood Marrow Transplant. 2009;15(Suppl 2):20–1.

    Google Scholar 

  52. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501–6.

    Article  CAS  PubMed  Google Scholar 

  53. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122(5):641–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, et al. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using The University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 2014;120(13):1975–84.

    Article  PubMed  Google Scholar 

  55. Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol. 2016;27:1940–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46–54.

    Article  CAS  PubMed  Google Scholar 

  57. Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A. Patient-reported outcomes in OAK: a phase III study of Atezolizumab versus Docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018. pii: S1525-7304(18)30131-1. https://doi.org/10.1016/j.cllc.2018.05.011.

  58. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903–9.

    Article  PubMed  Google Scholar 

  59. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu SQ, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1 alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656–66.

    Article  CAS  PubMed  Google Scholar 

  60. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, et al. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016;122:3401–9.

    Article  PubMed  Google Scholar 

  61. Mendoza TR, George G, Williams L, Shi Q, Naing A, Hong DS, et al, editors. Feasibility and added value of multiple baseline symptom assessments in early-phase clinical trials [abstract]. Presented at the International Society for Quality of Life Research (ISOQOL) 24th annual conference, Philadelphia; 2017.

    Google Scholar 

Download references

Conflicts of Interest

The author reports no conflict of interest in this work.

Author information

Authors and Affiliations

  1. Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Tito R. Mendoza

Authors
  1. Tito R. Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tito R. Mendoza .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, University of Texas, Houston, TX, USA

    Aung Naing

  2. Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mendoza, T.R. (2018). Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 995. Springer, Cham. https://doi.org/10.1007/978-3-030-02505-2_9

Download citation

Publish with us

Policies and ethics

Search

Navigation